Pemetrexed Fresenius Kabi 500 mg powder for concentrate for solution for infusion

DRUG2 trials

Sponsors

Regeneron Pharmaceuticals Inc., F. Hoffmann-La Roche AG

Conditions

Non-Small Cell Lung CancerPreviously Untreated Advanced or Metastatic Non-Squamous Non−Small Cell Lung Cancer

Phase 2

A Randomized Phase 2 Platform Study to Evaluate Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for the Perioperative Treatment of Patients with Resectable Non-Small Cell Lung Cancer

RecruitingCTIS2023-509806-31-00

Regeneron Pharmaceuticals Inc.Non-Small Cell Lung Cancer

Start: 2025-02-11Target: 40Updated: 2025-11-07

Phase 3

A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

RecruitingCTIS2024-518365-10-00

F. Hoffmann-La Roche AGPreviously Untreated Advanced or Metastatic Non-Squamous Non−Small Cell Lung Cancer

Start: 2025-10-28Target: 282Updated: 2026-01-13